February 17, 2018 09:14 AM EST

FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market

AstraZeneca $AZN has found a way to jump out in front of a pack of heavyweight PD-1/L1 rivals duking it out for a big piece …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA OK makes As­traZeneca the leader in one new seg­ment of the all-im­por­tant lung can­cer mar­ket